Apolipoprotein C1 (APOC1): A Novel Diagnostic and Prognostic Biomarker for Clear Cell Renal Cell Carcinoma
Apolipoprotein C1 (APOC1): A Novel Diagnostic and Prognostic Biomarker for Clear Cell Renal Cell Carcinoma
复制标题
DOI：
10.3389/fonc.2020.01436
复制
发表时间：
2020-08-20
影响因子：
4.7
通讯作者：
Liu, Bianjiang
中科院分区：
文献类型：
--
作者：
Cui, Yankang;Miao, Chenkui;Liu, Bianjiang
背景：载脂蛋白C1（Apolipoprotein C1，APOC 1）在胃癌、乳腺癌、肺癌和胰腺癌中起重要作用。然而，APOC 1与泌尿系肿瘤的关系尚不清楚。本研究旨在评估APOC 1在泌尿系肿瘤诊断和预后中的价值。方法：我们使用基因表达谱交互分析（GEPIA）数据库对泌尿系肿瘤中的APOC 1 mRNA表达进行了泛分析。为了进一步研究APOC 1表达在泌尿系癌症中的预后价值，使用Kaplan-Meier Kaplan-Meier数据库。此外，我们收集了32例ccRCC患者的肿瘤和邻近正常样本，以进行qRT-PCR和蛋白质印迹分析。共72例ccRCC患者使用组织微阵列（TMAs）进行了分析。结果：我们基于Kaplan-Meier Kaplan-Mean-Mean-Mean-Mean-Mean-Mean-Mean-Mean-Mean-Mean-Mean-Mean-Mean-Mean-Mean-Mean-Mean-Mean-Mean-Mean-Mean-Mean-Mean-Mean-Mean-Mean-Mean-Mean-Mean此外，根据UALCAN数据库，ccRCC的癌症分期和肿瘤分级似乎与APOC 1表达密切相关。因此，我们初步得出结论，APOC 1可能在ccRCC的肿瘤发生和进展中发挥关键作用。此外，对72例临床患者的Kaplan-Meier生存曲线分析表明，APOC 1的高表达与不良无进展生存期（PFS，p= 0.007）和OS（p= 0.022）相关。此外，单变量考克斯回归分析证实了APOC 1表达与生存率之间的显著关系（p= 0.038）。结合患者的临床病理特征进行TMAs分析。APOC 1的表达与肿瘤大小（p= 0.018）和组织学分级（p= 0.016）显著相关。结论：总之，我们的研究结果表明，APOC 1可能作为一种新的诊断和预后生物标志物的ccRCC。APOC 1促进肿瘤进展机制的进一步证据可能使其成为治疗ccRCC的新靶点。
Background:Apolipoprotein C1 (APOC1) has been proved to play a critical role in gastric, breast, lung, and pancreatic cancer. However, the relationship between APOC1 and urinary tumors remains unclear. This study aimed to assess the diagnostic and prognostic value of APOC1 in urinary tumors. Methods:We performed a pan analysis of APOC1 mRNA expression in urinary cancer using the Gene Expression Profiling Interactive Analysis (GEPIA) database. To further investigate the prognostic value of APOC1 expression in urinary cancers, the Kaplan-Meier plotter database was used. Furthermore, we collected the tumor and adjacent normal samples of 32 ccRCC patients to perform qRT-PCR and western blotting assays. A total of 72 cases with ccRCC were analyzed using tissue microarrays (TMAs). Results:Our results based on Kaplan-Meier plotter database indicated that a high expression of APOC1 may lead to poor overall survival (OS,p= 0.0019) in patients with ccRCC. Furthermore, the cancer stages and tumor grade of ccRCC appeared to be strongly linked with APOC1 expression according to UALCAN database. Hence, we reached a preliminary conclusion that APOC1 may play a key role in the tumorigenesis and progression of ccRCC. Furthermore, the Kaplan-Meier survival curve analyses of 72 clinical patients indicated that high expression of APOC1 was associated with poor progression-free survival (PFS,p= 0.007) and OS (p= 0.022). In addition, univariate Cox regression analysis confirmed the significant relationship between APOC1 expression and survival (p= 0.038). The TMAs analysis in combination with the patients' clinicopathological features was also performed. The expression of APOC1 was found to be significantly correlated with the tumor size (p= 0.018) and histological grade (p= 0.016). Conclusions:In conclusion, the findings of our study suggest that APOC1 may serve as a novel diagnostic and prognostic biomarker for ccRCC. Further evidence on the mechanism of APOC1 promoting tumor progression may transform it to a new therapeutic target for the treatment of ccRCC.